The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $35.00, about 393% above its August 12 closing price of $7.10.
Cash position and outlook
The company ended Q2 with $95.7 million in cash, equivalents, investments, and receivables.
Kyntra Bio expects an interim analysis of the FG-3246 Phase 2 trial in mCRPC in 4Q 2026.
It aims to initiate a pivotal Phase 3 trial of roxadustat in LR-MDS in 4Q 2026.
KYNB•
